ReviewAlzheimer's research & therapy2025
Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
Review in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Tau dysfunction in alzheimer's disease: molecular and cellular mechanisms, genetic modulation, and therapeutic perspectives.Molecular biology reports · 2026Review
- Patient-derived forebrain cortical organoids reveal biphasic tau-MAP6-microtubule axis dysfunction in tauopathy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Stable neuronal representations underlie cognitive resilience to Alzheimer's disease pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cognitive Impairment, Dementia and Depression in Older Adults.Journal of clinical medicine · 2026Review
- From clinical phenotypes to molecular precision: multimodal biomarkers for progressive supranuclear palsy.Frontiers in neuroscience · 2026Review
- Article
- Unclassifiable senile plaques and extensive cerebral amyloid angiopathy involving spinal and bridging vessels in autopsied patients with Down syndrome.Free neuropathology · 2026Article
- Tau-Mitochondria Interactions in Neurodegeneration: Mechanisms and Therapeutic Potential.Cellular and molecular neurobiology · 2025Review
- Intepirdine Derivatives Possessing Dual 5HT6 Antagonism / HDAC6 Inhibitory Activity.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025Article
- Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures.Cells · 2025Review
- Therapeutic and preventive strategies based on the maladaptive plasticity hypothesis for Alzheimer's disease.Frontiers in aging neuroscience · 2025Article
- Oncology drug repurposing as a blueprint for Alzheimer's therapy.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microtubule associated protein tau (MAPT) is a naturally occurring protein that plays a significant role in stabilizing microtubules, which are essential for the transport of nutrients and other materials within neurons. In tauopathies, tau protein assembles into mis-folded multimers ranging from soluble oligomers to insoluble aggregates, known as neurofibrillary tangles, neuropil threads and are components of neuritic plaques. These abnormal tau assemblies collectively are thought to disrupt the normal function of neurons and lead to their death. Tauopathies are a leading cause of neurodegeneration, and there are no approved disease modifying therapies targeting the tau pathology for any tauopathy. This review is a two-year update to an initial review of preclinical, clinical, and recently discontinued therapeutic programs in development focused on ameliorating tau pathology. This review outlines the landscape of therapeutic drugs indexed through January 1, 2025. Currently, there are 170 drugs monitored in the pipeline, one less than in the previous period. In the clinic, there are five candidates in phase 3 trials, 15 in phase 2 trials, and 12 in phase 1 trials. In total, there are four less candidates in clinical trials during this review period than the last. New to this review is the inclusion of the clinical development of tau positron emission tomography (PET) ligands which undergo regulatory oversite. In addition to the one FDA-approved tau PET ligand Tauvid™ (flortaucipir), there are six additional tau PET ligands currently in active clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.